

Consolidated Financial Results for Fiscal 2016

(Reference Data of Financial Statements for the 3Q of Fiscal 2016)

February 6, 2017

KAKEN PHARMACEUTICAL CO., LTD.

Corporate Communications

Tel: +81-(0)3-5977-5002

Fax: +81-(0)3-5977-5131

Email: koho@kaken.co.jp

1. Summary of Consolidated Financial Statements for the Third Quarter of Fiscal 2016

(Figures less than one million yen have been omitted)

	FY2015 3rd Q	FY2015	FY2016 3rd Q	Y o Y increase (decrease)		FY2016 Forecasts	Y o Y increase (decrease)	
				Yen	%		Yen	%
Net sales	85,431	109,730	78,965	(6,465)	92.4%	106,100	(3,630)	96.7%
Operating income	29,689	35,146	24,953	(4,736)	84.0%	28,900	(6,246)	82.2%
Ratio of net sales	34.8%	32.0%	31.6%			27.2%		
Ordinary income	29,919	35,365	25,232	(4,686)	84.3%	29,100	(6,265)	82.3%
Ratio of net sales	35.0%	32.2%	32.0%			27.4%		
Net income	20,134	21,143	17,983	(2,150)	89.3%	20,800	(343)	98.4%
Ratio of net sales	23.6%	19.3%	22.8%			19.6%		
Comprehensive income	20,711	18,444	18,782	(1,929)	90.7%			
R&D expenses	4,392	5,883	4,985	592	113.5%	10,200	4,317	173.4%

2. Breakdown of Sales by Main Pharmaceuticals and Medical Devices

(Figures less than one million yen have been omitted)

	FY2015 3rd Q	FY2015	FY2016 3rd Q	%	FY2016 Forecasts	%
Anti-osteoarthritis Artz	24,250	30,760	23,056	95.1%	29,800	96.9%
Anti-nail fungus Clenafin	15,385	19,868	17,349	112.8%	23,300	117.3%
Post-operative anti-adhesive Seprafilm	8,711	11,262	8,584	98.5%	11,400	101.2%
Anti-hyperlipidemia Lipidil	3,495	4,526	3,436	98.3%	4,400	97.2%
Wound healing agent Fiblast Spray	2,723	3,617	2,782	102.2%	3,700	102.3%
Generic products	10,237	13,292	9,195	89.8%	12,700	95.5%
Sales of Jublia*	4,986	5,722	2,188	43.9%	4,100	71.7%

(*including sales of API and finished product, royalty revenue, milestone revenue and initial payment)